Results 161 to 168 of about 10,563 (168)
Some of the next articles are maybe not open access.

Related searches:

Interim Restaging FDG-PET/CT to Guide Use of High Dose Sequential Induction Therapy with Rituximab-Dose-Intensive Cyclophosphamide, Etoposide, Cisplatin (RDICEP) and Rituximab-Carmustine, Etoposide, Cytarabine, Melphalan (RBEAM) and Autologous Stem Cell Transplantation (ASCT) for Poor Prognosis Diffuse Large B-Cell Lymphoma (DLBCL). ClinicalTrials. Gov Identifier: NCT00530179.

Blood, 2009
Abstract Abstract 3414 Poster Board III-302 Purpose Approximately 50-55% of patients (pts) with stage 3-4 DLBCL and elevated serum LDH achieve long-term event-free survival (EFS) following R-CHOP chemotherapy.
Douglas A. Stewart   +8 more
openaire   +1 more source

Result disclosure on ClinicalTrials. gov — first experiences and challenges

Pharmaceutical Programming, 2010
AbstractThe disclosure of clinical trial 'basic' results on the website ClinicalTrials. gov has been legally required since September 2008 for all FDA-approved trials or cleared drugs and devices. Since that time, many additions (e.g.adverse event reporting in September 2009) and corrections (both content and format related) have been implemented.
openaire   +1 more source

T1192 A Randomized Trial of Metabolite-Adjusted Versus Weight-Based Dosing of Azathioprine (AZA) in Crohn's Disease (CD) [Clinicaltrials. Gov Identifier Nct00113503]

Gastroenterology, 2009
Themistocles Dassopoulos   +6 more
openaire   +1 more source

CHARACTERISTICS AND TRENDS OF CARDIOVASCULAR TRIALS: ANALYSIS OF CLINICALTRIALS. GOV LISTINGS FROM 2008 TO 2022

Journal of the American College of Cardiology
Gerald Chi   +8 more
openaire   +1 more source

Home - About - Disclaimer - Privacy